These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
97 related articles for article (PubMed ID: 9118466)
1. Adrenal proteins bound by a reactive intermediate of mitotane. Cai W; Counsell RE; Schteingart DE; Sinsheimer JE; Vaz AD; Wotring LL Cancer Chemother Pharmacol; 1997; 39(6):537-40. PubMed ID: 9118466 [TBL] [Abstract][Full Text] [Related]
2. Metabolic activation and binding of mitotane in adrenal cortex homogenates. Cai W; Counsell RE; Djanegara T; Schteingart DE; Sinsheimer JE; Wotring LL J Pharm Sci; 1995 Feb; 84(2):134-8. PubMed ID: 7738789 [TBL] [Abstract][Full Text] [Related]
3. Bovine adrenal cortex transformations of mitotane [1-(2-chlorophenyl)-1-(4-chlorophenyl)-2,2-dichloroethane; o,p'-DDD] and its p,p'- and m,p'-isomers. Cai W; Benitez R; Counsell RE; Djanegara T; Schteingart DE; Sinsheimer JE; Wotring LL Biochem Pharmacol; 1995 May; 49(10):1483-9. PubMed ID: 7763292 [TBL] [Abstract][Full Text] [Related]
4. Comparative CYP-dependent binding of the adrenocortical toxicants 3-methylsulfonyl-DDE and o,p'-DDD in Y-1 adrenal cells. Hermansson V; Asp V; Bergman A; Bergström U; Brandt I Arch Toxicol; 2007 Nov; 81(11):793-801. PubMed ID: 17487473 [TBL] [Abstract][Full Text] [Related]
5. Association of mitotane with chylomicrons and serum lipoproteins: practical implications for treatment of adrenocortical carcinoma. Kroiss M; Plonné D; Kendl S; Schirmer D; Ronchi CL; Schirbel A; Zink M; Lapa C; Klinker H; Fassnacht M; Heinz W; Sbiera S Eur J Endocrinol; 2016 Mar; 174(3):343-53. PubMed ID: 26671975 [TBL] [Abstract][Full Text] [Related]
6. Cytochrome P450-catalyzed binding of 3-methylsulfonyl-DDE and o,p'-DDD in human adrenal zona fasciculata/reticularis. Lindhe O; Skogseid B; Brandt I J Clin Endocrinol Metab; 2002 Mar; 87(3):1319-26. PubMed ID: 11889204 [TBL] [Abstract][Full Text] [Related]
7. Modulation of proteomic profile in H295R adrenocortical cell line induced by mitotane. Stigliano A; Cerquetti L; Borro M; Gentile G; Bucci B; Misiti S; Piergrossi P; Brunetti E; Simmaco M; Toscano V Endocr Relat Cancer; 2008 Mar; 15(1):1-10. PubMed ID: 18310271 [TBL] [Abstract][Full Text] [Related]
8. Mitotane increases the radiotherapy inhibitory effect and induces G2-arrest in combined treatment on both H295R and SW13 adrenocortical cell lines. Cerquetti L; Bucci B; Marchese R; Misiti S; De Paula U; Miceli R; Muleti A; Amendola D; Piergrossi P; Brunetti E; Toscano V; Stigliano A Endocr Relat Cancer; 2008 Jun; 15(2):623-34. PubMed ID: 18509009 [TBL] [Abstract][Full Text] [Related]
9. Metabolism and covalent binding of 1-(o-chlorophenyl)-1-(p-chlorophenyl)-2,2-dichloroethane (o,p,'-DDD). Correlation between adrenocorticolytic activity and metabolic activation by adrenocortical mitochondria. Martz F; Straw JA Drug Metab Dispos; 1980; 8(3):127-30. PubMed ID: 6104572 [No Abstract] [Full Text] [Related]
10. The in vitro metabolism of 1-(o-chlorophenyl)-1-(p-chlorophenyl)-2,2-dichloroethane (o,p'-DDD) by dog adrenal mitochondria and metabolite covalent binding to mitochondrial macromolecules: a possible mechanism for the adrenocorticolytic effect. Martz F; Straw JA Drug Metab Dispos; 1977; 5(5):482-6. PubMed ID: 20298 [No Abstract] [Full Text] [Related]
11. Mitotane alters mitochondrial respiratory chain activity by inducing cytochrome c oxidase defect in human adrenocortical cells. Hescot S; Slama A; Lombès A; Paci A; Remy H; Leboulleux S; Chadarevian R; Trabado S; Amazit L; Young J; Baudin E; Lombès M Endocr Relat Cancer; 2013 Jun; 20(3):371-81. PubMed ID: 23696597 [TBL] [Abstract][Full Text] [Related]
12. In vitro biotransformations of 1-(o-chlorophenyl)-1-(p-chlorophenyl)-2,2-dichloroethane (o,p'-DD) and 1,1-bis(p-chlorophenyl)-2,2-dichloroethane (p,p'-DDD) by bovine adrenal. Reif VD; Littleton BC; Sinesheimer JE J Agric Food Chem; 1975; 23(5):996-9. PubMed ID: 1159206 [No Abstract] [Full Text] [Related]
13. Structural requirements for mitotane activity: development of analogs for treatment of adrenal cancer. Schteingart DE; Sinsheimer JE; Benitez RS; Homan DF; Johnson TD; Counsell RE Anticancer Res; 2012 Jul; 32(7):2711-20. PubMed ID: 22753730 [TBL] [Abstract][Full Text] [Related]
14. Treatment with o,p'-DDD (mitotane) decreased cytochrome P-450, heme, and microsomal protein content in the dog adrenal cortex in vivo. Martz F; Straw JA Res Commun Chem Pathol Pharmacol; 1976 Jan; 13(1):83-92. PubMed ID: 1257603 [TBL] [Abstract][Full Text] [Related]
15. [Cholesterol-hydroxylating cytochrome P-450 from bovine adrenal cortex mitochondria and human placenta: immunochemical properties and structural characteristics]. Usanov SA; Chernogolov AA; Honkakoski P; Lang M; Passanen M; Raunio H; Pelkonen O Biokhimiia; 1990 May; 55(5):865-77. PubMed ID: 2393675 [TBL] [Abstract][Full Text] [Related]
16. Effects of mitotane on gene expression in the adrenocortical cell line NCI-H295R: a microarray study. Zsippai A; Szabó DR; Tömböl Z; Szabó PM; Eder K; Pállinger E; Gaillard RC; Patócs A; Tóth S; Falus A; Rácz K; Igaz P Pharmacogenomics; 2012 Sep; 13(12):1351-61. PubMed ID: 22966885 [TBL] [Abstract][Full Text] [Related]
17. [The effect of o,p'-dichlorodiphenyldichloroethane on malic enzyme activity of the adrenal glands]. Mikosha AS Vopr Med Khim; 1985; 31(1):61-4. PubMed ID: 3984275 [TBL] [Abstract][Full Text] [Related]
18. Conventional and novel strategies in the treatment of adrenocortical cancer. Schteingart DE Braz J Med Biol Res; 2000 Oct; 33(10):1197-200. PubMed ID: 11004720 [TBL] [Abstract][Full Text] [Related]
19. Adjuvant mitotane therapy of adrenal cancer - use and controversy. Schteingart DE N Engl J Med; 2007 Jun; 356(23):2415-8. PubMed ID: 17554125 [No Abstract] [Full Text] [Related]
20. Effect of o,p'-DDD and Li+ on apoptotic DNA fragmentation in conventionally normal and tumour tissues of human adrenal cortex. Pushkarev VM; Tronko ND; Kostyuchenko NN; Mikosha AS Ukr Biokhim Zh (1999); 2007; 79(2):44-9. PubMed ID: 18030749 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]